 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- carbon monoxide (HBI-002) / Hillhurst Biopharma, HB-002 / Zhejiang Huahai Pharma, HB-002 M / Zhejiang Huahai Pharma
[VIRTUAL] NEUROPROTECTION OF LOW DOSE CARBON MONOXIDE IN GENETIC AND TOXIN MODELS OF PARKINSON’S DISEASE () - Dec 24, 2020 - Abstract #ADPD2021ADPD_1363;
Low-dose CO protects nigral dopamine neurons, preserves striatal dopamine content, and reduces aSyn pathology in animal models of PD. Low dose CO may have disease-modifying activity in PD.
- || HB002.1M / Zhejiang Huahai Pharma
Trial completion, Enrollment change: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Aug 8, 2020
P1, N=21, Completed, Sponsor: Huabo Biopharm Co., Ltd.
Low dose CO may have disease-modifying activity in PD. Recruiting --> Completed | N=30 --> 21
- | HB002.1M / Zhejiang Huahai Pharma
Trial primary completion date: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Feb 12, 2020
P1, N=30, Recruiting, Sponsor: Huabo Biopharm Co., Ltd.
Recruiting --> Completed | N=30 --> 21 Trial primary completion date: Dec 2019 --> Mar 2020
- | HB002.1M / Zhejiang Huahai Pharma
Trial completion date, Trial primary completion date: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - May 8, 2019
P1, N=30, Recruiting, Sponsor: Huabo Biopharm Co., Ltd.
Trial primary completion date: Dec 2019 --> Mar 2020 Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> Dec 2019
- | HB002.1M / Zhejiang Huahai Pharma
Enrollment open, Trial initiation date: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 1, 2018
P1, N=30, Recruiting, Sponsor: Huabo Biopharm Co., Ltd.
Trial completion date: Dec 2019 --> Jun 2020 | Trial primary completion date: Jul 2019 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018
- | HB002.1M / Zhejiang Huahai Pharma
New P1 trial: A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 2, 2018
P1, N=30, Not yet recruiting, Sponsor: Huabo Biopharm Co., Ltd.